Market reaction to Sanofi's upcoming litigation over Zantac is 'overblown,' analysts say

A sudden downturn in the market value of Sanofi—largely fueled by concerns about upcoming multi-district litigation in the United States over heartburn drug Zantac—has some declaring that the sky is falling for the French pharma.